Patient Registries Prove Value As Drug Development Tools
This article was originally published in Scrip
Executive Summary
It's easy for pharmaceutical and biotechnology companies to get caught up in biomarkers and scientific clinical endpoints as the end goals in drug development, but a novel, practical approach is gaining momentum: asking the patient what they need or want from new medicines.